Brief: Akili Inc Announces Results From Pivotal Trial Of Endeavorrx In Adolescents With ADHD
05/01/2023 12:14
Jan 5 (Reuters) - Akili Inc AKLI.O :
* PIVOTAL TRIAL OF ENDEAVORRXⓇ IN ADOLESCENTS WITH ADHD
SHOWS
ROBUST IMPROVEMENTS IN ATTENTION AND BROADER CLINICAL OUTCOMES
* AKILI INC - STUDY DATA WILL BE USED TO FILE FOR ENDEAVORRX
LABEL
EXPANSION WITH FDA IN 2023
* AKILI INC - AKILI HAS STOPPED RECRUITMENT IN SEPARATE
ADULT ADHD
TRIAL TO ALLOW FOR EARLIER DATA ANALYSIS
Source text for Eikon: ID:nBw7D7RyWa
Further company coverage: AKLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akili
See all newsBrief: Akili Announces FDA Authorization Of Endeavorotc, The First FDA Clearance Of A Digital Treatment For Adults With Adhd Through A Video Game
Brief: Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement To Establish Leading Digital Health Company
Akili Inc reports results for the quarter ended in March - Earnings Summary
Akili Inc expected to post a loss of 14 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery